These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28947024)

  • 1. Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler - Results from a non-interventional study.
    Schmidt O; Petro W; Hoheisel G; Kanniess F; Oepen P; Langer-Brauburger B
    Respir Med; 2017 Oct; 131():166-174. PubMed ID: 28947024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
    O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
    J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial.
    Balki A; Balamurugan S; Bardapurkar S; Dalal S; Singh A; Singh BP; Vaidya A; Gogtay JA
    Pulm Pharmacol Ther; 2018 Feb; 48():28-36. PubMed ID: 28890299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget impact analysis of a fixed-dose combination of fluticasone propionate and formoterol fumarate (FP/FORM) in a pressurized metered-dose inhaler (pMDI) for asthma.
    Dunlop W; Heron L; Fox G; Greaney M
    Adv Ther; 2013 Oct; 30(10):933-44. PubMed ID: 24194361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An innovative corticosteroid/long-acting β
    Usmani O; Roche N; Marshall J; Danagher H; Price D
    Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
    [No Abstract]   [Full Text] [Related]  

  • 6. Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management.
    Backer V; Ellery A; Borzova S; Lane S; Kleiberova M; Bengtsson P; Tomala T; Basset-Stheme D; Bennett C; Lindner D; Meiners A; Overend T
    Ther Adv Respir Dis; 2018; 12():1753466618796987. PubMed ID: 30232933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
    Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
    Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effects of two inhaled corticosteroid/long-acting β₂-agonist combinations in the treatment of asthma.
    Yatera K; Yamasaki K; Nishida C; Noguchi S; Oda K; Akata K; Nagata S; Kawanami Y; Kawanami T; Ishimoto H; Mukae H
    J Asthma; 2014 Sep; 51(7):762-8. PubMed ID: 24654703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β
    Price DB; Carter V; Martin J; Gardener EA; Skinner D; Yang S; Hoffman M; Willis JC; Cooper AJ
    Drugs; 2020 Jan; 80(1):47-60. PubMed ID: 31749061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.
    Corren J; Mansfield LE; Pertseva T; Blahzko V; Kaiser K
    Respir Med; 2013 Feb; 107(2):180-95. PubMed ID: 23273405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid monotherapy.
    Hozawa S; Terada M; Hozawa M
    Pulm Pharmacol Ther; 2014 Apr; 27(2):190-6. PubMed ID: 24388868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
    Frois C; Wu EQ; Ray S; Colice GL
    Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation.
    Wan Yau Ming S; Haughney J; Small I; Wolfe S; Hamill J; Gruffydd-Jones K; Daly C; Soriano JB; Gardener E; Skinner D; Stagno d'Alcontres M; Price DB
    Respir Med; 2017 Aug; 129():199-206. PubMed ID: 28732831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma].
    Korn S; Vogelmeier C; Buhl R
    Med Klin (Munich); 2008 May; 103(5):299-310. PubMed ID: 18484216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
    Papi A; Corradi M; Pigeon-Francisco C; Baronio R; Siergiejko Z; Petruzzelli S; Fabbri LM; Rabe KF
    Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on small airway obstruction of long-term treatments with beclomethasone/formoterol hydrofluoroalkane (metered-dose inhaler) versus fluticasone/salmeterol (dry-powder inhaler) in asthma: a preliminary study.
    Corda L; Gardenghi GG; Modina D; Montemurro LT; Novali M; Tantucci C
    Allergy Asthma Proc; 2011; 32(6):29-34. PubMed ID: 22221427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients.
    Price D; Small I; Haughney J; Ryan D; Gruffydd-Jones K; Lavorini F; Harris T; Burden A; Brockman J; King C; Papi A
    Prim Care Respir J; 2013 Dec; 22(4):439-48. PubMed ID: 24186700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life.
    Price DB; Williams AE; Yoxall S
    Respir Res; 2007 Jul; 8(1):46. PubMed ID: 17610727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.